GSK has just announced first quarter sales and they actually mentioned Relenza in a paragraph, although they said revenue was down 25% from the same quarter last year due to Japan not repeating stockpiling in 2015.
The GSK Relenza revenue was £30m or approx $US46m.
Unfortunately it is listed amongst "Other" in their table of sales, so we cannot track its sales in different regions...
...speaking of which, I recall Relenza Patents in Europe run out this month - can anyone confirm?
Anyway, 7% of 46m = a whopping $3.2m royalties from GSK for that quarter.
DS results should be due soon. Their last quarter Inavir sales (not sure whether they were reported here) were up 6% YoY, so will be interesting to see what the latest quarter figures are.
Anything to stem a little cash burn at this stage...while we wait for JP to pull a rabbit out of his hat.
Ahoy Joseph - what's been happening?
BTA Price at posting:
57.0¢ Sentiment: None Disclosure: Held
